Skip to content

Arrowhead Research ARWR Debt Issuance Costs

Debt Issuance Costs at other companies

Revvity logo
RevvityRVTY
$0-100%
Moderna logo
ModernaMRNA
$5.5M
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's debt issuance costs?
Arrowhead Research (ARWR) reported debt issuance costs of $18.72M in Q1 2026.
What does debt issuance costs mean?
Cash paid to cover the costs of issuing debt.
How do you interpret debt issuance costs?
Higher costs relative to debt issued may indicate less favorable borrowing terms or complex financing structures.
How does debt issuance costs compare across companies?
Varies based on the size and complexity of the debt instrument; peers typically report this as a small percentage of total debt raised.